PANDO and MGD in Postmenopausal Women: A Cross-Sectional Study of 272 Patients

A dataset from a prospective cross-sectional study of 272 postmenopausal women, including 180 with primary acquired nasolacrimal duct obstruction (PANDO) and 92 controls. The data includes standardized assessments of meibomian gland dysfunction (MGD), such as meibography for gland loss, slit-lamp evaluations, and Ocular Surface Disease Index (OSDI) questionnaire scores, along with exploratory tear cytokine and serum hormone analyses. The dataset was authored by Haili Jin and last updated on 2026-04-30.

Use Cases

• Identify risk factors for severe meibomian gland loss based on the completeness of nasolacrimal duct obstruction.
• Analyze the association between PANDO disease duration and meibomian gland expressibility impairment.
• Model the relationship between non-invasive tear meniscus height and tear breakup time.
• Investigate demographic, clinical, and hormonal factors associated with MGD in a postmenopausal population.

Strengths

• Includes data from 272 postmenopausal women, with 180 in the PANDO group and 92 controls.
• Contains standardized clinical assessments: meibography, slit-lamp evaluation, and OSDI questionnaire scores.
• Features exploratory biomarker data from tear cytokine (n=71) and serum hormone (n=98) analyses.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small in size (14.8 KB), indicating a limited scope of data.

Provenance

Source

figshare

Collection Method

Prospective cross-sectional study with standardized clinical assessments.

Freshness

Last updated 2026-04-30 04:16:32; freshness should be verified.